Study: Companies regularly don’t tell investors why FDA rejected their drugs
A study in the British Medical looked at company press releases found that they frequently held back information about why the FDA rejected a drug.
Rookie of the Year: Forbes says Keytruda & Opdivo are 2014’s most important new drugs
What was the best new drug of 2014? Forbes‘ Matthew Herper chose two. Herper laid out a solid case for why two new – and highly similar – cancer drugs are standouts this year: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. He writes: These two medicines represent a breakthrough in oncology: unlocking the immune system as a […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.